These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 2430229)
1. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Ferraro TN; Golden GT; DeMattei M; Hare TA; Fariello RG Neuropharmacology; 1986 Sep; 25(9):1071-4. PubMed ID: 2430229 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues. Fries DS; de Vries J; Hazelhoff B; Horn AS J Med Chem; 1986 Mar; 29(3):424-7. PubMed ID: 3485197 [TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Youngster SK; Sonsalla PK; Heikkila RE J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590 [TBL] [Abstract][Full Text] [Related]
5. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Battaglia G; Busceti CL; Molinaro G; Biagioni F; Storto M; Fornai F; Nicoletti F; Bruno V J Neurosci; 2004 Jan; 24(4):828-35. PubMed ID: 14749427 [TBL] [Abstract][Full Text] [Related]
6. Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Perry TL; Yong VW; Jones K; Wright JM Neurosci Lett; 1986 Oct; 70(2):261-5. PubMed ID: 3490637 [TBL] [Abstract][Full Text] [Related]
7. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525 [TBL] [Abstract][Full Text] [Related]
8. Persistent depletion of striatal dopamine and its metabolites in mice by TMMP, an analogue of MPTP. Fuller RW; Hemrick-Luecke SK J Pharm Pharmacol; 1987 Aug; 39(8):667-9. PubMed ID: 2888865 [TBL] [Abstract][Full Text] [Related]
9. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Yong VW; Perry TL; Krisman AA Neurosci Lett; 1986 Jan; 63(1):56-60. PubMed ID: 3485266 [TBL] [Abstract][Full Text] [Related]
10. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
11. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1). Sheng JG; Xu DL; Yu HZ; Xu XR; Tang QM Life Sci; 1987 May; 40(20):2007-10. PubMed ID: 2437428 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors. Fuller RW; Hemrick-Luecke SK; Robertson DW Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):57-65. PubMed ID: 2417293 [TBL] [Abstract][Full Text] [Related]
13. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Sonsalla PK; Heikkila RE Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988 [TBL] [Abstract][Full Text] [Related]
14. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP. Fuller RW; Hemrick-Luecke SK Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080 [TBL] [Abstract][Full Text] [Related]
16. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT. Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755 [TBL] [Abstract][Full Text] [Related]
17. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion. Oeckl P; Scheffold A; Lechel A; Rudolph KL; Ferger B Neuroreport; 2014 Mar; 25(5):335-9. PubMed ID: 24525820 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Heikkila RE; Hess A; Duvoisin RC Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525 [TBL] [Abstract][Full Text] [Related]
19. Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP). Fuller RW; Robertson DW; Hemrick-Luecke SK Biochem Pharmacol; 1986 Jan; 35(2):143-4. PubMed ID: 3484628 [No Abstract] [Full Text] [Related]
20. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]